|
ATE534415T1
(de)
|
2005-12-13 |
2011-12-15 |
Harvard College |
Gerüste zur zelltransplantation
|
|
HRP20200310T1
(hr)
|
2010-10-06 |
2020-08-21 |
President And Fellows Of Harvard College |
Hidrogelovi koji stvaraju pore pogodni za injekcije, namijenjeni staničnim terapijama na bazi materijala
|
|
AU2013249366B2
(en)
|
2012-04-16 |
2018-02-01 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
|
CA2876150A1
(en)
|
2012-06-08 |
2013-12-12 |
The Johns Hopkins University |
Compostions and methods for cancer immunotherapy
|
|
KR20150095668A
(ko)
|
2012-12-13 |
2015-08-21 |
아두로 바이오테크, 인코포레이티드 |
규정된 입체화학을 갖는 환식 퓨린 다이뉴클레오타이드를 포함하는 조성물, 그리고 이의 제조 방법 및 용도
|
|
WO2014179335A1
(en)
|
2013-04-29 |
2014-11-06 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
EP2992000B1
(en)
|
2013-05-03 |
2020-07-08 |
The Regents of The University of California |
Cyclic di-nucleotide induction of type i interferon
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
SI2996473T1
(sl)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech, Inc. |
Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov"
|
|
EP3027227A4
(en)
*
|
2013-07-31 |
2018-05-23 |
Memorial Sloan Kettering Cancer Center |
Sting crystals and modulators
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
US20160287623A1
(en)
*
|
2013-11-19 |
2016-10-06 |
The University Of Chicago |
Use of sting agonist as cancer treatment
|
|
CA2974651A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
|
ES2692226T3
(es)
|
2014-06-04 |
2018-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dinucleótidos cíclicos como moduladores de STING
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
MA40035A
(fr)
|
2014-10-14 |
2016-04-21 |
Dana Farber Cancer Inst Inc |
Molécules d'anticorps de pd-l1 et leurs utilisations
|
|
WO2016079899A1
(ja)
*
|
2014-11-20 |
2016-05-26 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
|
|
EP3233882B1
(en)
|
2014-12-16 |
2019-10-30 |
Kayla Therapeutics |
Fluorinated cyclic dinucleotides for cytokine induction
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3250250A4
(en)
*
|
2015-01-30 |
2019-05-22 |
President and Fellows of Harvard College |
PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
|
|
CA3013713A1
(en)
|
2015-02-11 |
2016-08-18 |
The Johns Hopkins University |
Bacteria over-expressing c-di-amp and therapeutic methods
|
|
MX2017011597A
(es)
|
2015-03-10 |
2018-05-11 |
Aduro Biotech Inc |
Composiciones y metodos para activar la señalizacion dependiente del "estimulador del gen de interferon".
|
|
HK1249452A1
(zh)
|
2015-04-10 |
2018-11-02 |
President And Fellows Of Harvard College |
免疫細胞捕獲裝置及其製備和使用方法
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
|
WO2017019896A1
(en)
*
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
CN106692967A
(zh)
*
|
2015-08-12 |
2017-05-24 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合PD1的抗体（Nivolumab）在制备抗肿瘤药物中的应用
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CA2995365C
(en)
*
|
2015-08-13 |
2021-10-12 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN106540255A
(zh)
*
|
2015-09-18 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用
|
|
UY36969A
(es)
|
2015-10-28 |
2017-05-31 |
Novartis Ag |
Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
EP3322713B1
(en)
|
2015-12-03 |
2021-01-20 |
GlaxoSmithKline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
|
US20180369268A1
(en)
*
|
2015-12-16 |
2018-12-27 |
Aduro Biotech, Inc. |
Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
|
|
KR20180107102A
(ko)
|
2015-12-16 |
2018-10-01 |
그릿스톤 온콜로지, 인코포레이티드 |
신생항원 동정, 제조, 및 용도
|
|
BR112018012138A2
(pt)
|
2015-12-17 |
2018-12-04 |
Novartis Ag |
moléculas de anticorpo para pd-1 e usos das mesmas
|
|
CN108473569B
(zh)
|
2016-01-11 |
2022-11-22 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
CA3011528A1
(en)
|
2016-01-11 |
2017-07-20 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
CN106544319A
(zh)
*
|
2016-01-24 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法
|
|
CN109072197A
(zh)
|
2016-02-06 |
2018-12-21 |
哈佛学院校长同事会 |
重塑造血巢以重建免疫
|
|
AU2017233068C1
(en)
*
|
2016-03-18 |
2023-05-25 |
Immune Sensor, Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
CN106540256A
(zh)
*
|
2016-03-27 |
2017-03-29 |
聊城市奥润生物医药科技有限公司 |
环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
|
|
HUE058932T2
(hu)
|
2016-04-07 |
2022-09-28 |
Glaxosmithkline Ip Dev Ltd |
Fehérjemodulátorokként hasznos heterociklikus amidok
|
|
EA201892128A1
(ru)
|
2016-04-07 |
2019-04-30 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Гетероциклические амиды, полезные в качестве модуляторов
|
|
WO2017184735A1
(en)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
|
EP3445761A1
(en)
|
2016-04-19 |
2019-02-27 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
US10696985B1
(en)
|
2016-06-06 |
2020-06-30 |
Vanderbilt University |
Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018009652A1
(en)
*
|
2016-07-06 |
2018-01-11 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
MX392605B
(es)
*
|
2016-07-06 |
2025-03-11 |
Invox Pharma Ltd |
Compuestos, composiciones y metodos para el tratamiento de enfermedades.
|
|
DK3484448T3
(da)
|
2016-07-13 |
2025-06-10 |
Harvard College |
Antigenpræsenterende cellemimetiske stilladser og fremgangsmåder til fremstilling og brug af disse
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
AU2017305345B2
(en)
|
2016-08-02 |
2024-09-05 |
President And Fellows Of Harvard College |
Biomaterials for modulating immune responses
|
|
CA3069780A1
(en)
|
2016-08-09 |
2018-02-15 |
Aarhus Universitet |
Modulation of ifi16 and sting activity
|
|
CN110121335A
(zh)
|
2016-08-30 |
2019-08-13 |
达纳-法伯癌症研究所股份有限公司 |
药物递送组合物及其用途
|
|
US11052149B2
(en)
|
2016-09-19 |
2021-07-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for inducing an immune response
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
MX386187B
(es)
|
2016-10-04 |
2025-03-18 |
Merck Sharp & Dohme Llc |
Compuestos de benzo[b]tiofeno como agonistas de sting.
|
|
EP3523314A1
(de)
|
2016-10-07 |
2019-08-14 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
|
EP3525817A4
(en)
|
2016-10-11 |
2020-09-16 |
The Governors of the University of Alberta |
HEPATITIS C VIRUS-BASED IMMUNOGENIC COMPOSITIONS INCLUDING AS ADJUSTING A CYCLIC DINULEOTIDE OR ARCHAEOSOME AND THEIR METHODS OF USE
|
|
JOP20170188A1
(ar)
*
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JP2018090562A
(ja)
*
|
2016-12-01 |
2018-06-14 |
武田薬品工業株式会社 |
環状ジヌクレオチド
|
|
JOP20170192A1
(ar)
*
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
EP3558358A4
(en)
*
|
2016-12-20 |
2020-09-30 |
Merck Sharp & Dohme Corp. |
COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDIC STING AGONISTS FOR CANCER TREATMENT
|
|
EP3558324A4
(en)
*
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT
|
|
WO2018138685A2
(en)
*
|
2017-01-27 |
2018-08-02 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
CN110234404A
(zh)
|
2017-01-27 |
2019-09-13 |
詹森生物科技公司 |
作为sting激动剂的环状二核苷酸
|
|
BR112019015797A2
(pt)
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
EP3585379A4
(en)
|
2017-02-21 |
2020-12-02 |
Board of Regents, The University of Texas System |
CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR
|
|
CN106727331B
(zh)
*
|
2017-03-13 |
2022-02-01 |
杭州星鳌生物科技有限公司 |
免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
|
|
JP2020514378A
(ja)
|
2017-03-20 |
2020-05-21 |
ジェノセア バイオサイエンシーズ， インコーポレイテッド |
処置方法
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
CN118267470A
(zh)
|
2017-04-13 |
2024-07-02 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
|
KR102808275B1
(ko)
|
2017-04-14 |
2025-05-20 |
탈락 테라퓨틱스, 인크. |
면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
WO2018208667A1
(en)
*
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN108853144A
(zh)
*
|
2017-05-16 |
2018-11-23 |
科济生物医药（上海）有限公司 |
Toll样受体激动剂与免疫效应细胞的联用
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
SG11202000248UA
(en)
|
2017-07-14 |
2020-02-27 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
EP3431484A1
(en)
*
|
2017-07-21 |
2019-01-23 |
Ludwig-Maximilians-Universität München |
A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
|
|
WO2019023459A1
(en)
*
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
|
EP3661499A4
(en)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme Corp. |
COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO AGONISTS [B
|
|
WO2019027858A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
|
|
JP7311514B2
(ja)
|
2017-08-30 |
2023-07-19 |
ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド |
インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド
|
|
US10953032B2
(en)
*
|
2017-08-31 |
2021-03-23 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
JP7270608B2
(ja)
|
2017-08-31 |
2023-05-10 |
エフ－スター・セラピューティクス・インコーポレイテッド |
化合物、組成物、及び疾患の治療方法
|
|
JP7209697B2
(ja)
*
|
2017-08-31 |
2023-01-20 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
|
EP4327882A3
(en)
|
2017-09-08 |
2024-05-15 |
The Board of Trustees of the Leland Stanford Junior University |
Enpp1 inhibitors and their use for the treatment of cancer
|
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
US11584774B2
(en)
|
2017-09-11 |
2023-02-21 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
CN111417630B
(zh)
|
2017-10-05 |
2023-06-06 |
葛兰素史克知识产权开发有限公司 |
干扰素基因刺激因子(sting)的调节剂
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
ES3029080T3
(en)
|
2017-10-10 |
2025-06-23 |
Seattle Project Corp |
Neoantigen identification using hotspots
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
CN111566119A
(zh)
|
2017-11-10 |
2020-08-21 |
武田药品工业有限公司 |
Sting调节剂化合物以及制备和使用方法
|
|
EA038805B1
(ru)
*
|
2017-11-21 |
2021-10-21 |
Такеда Фармасьютикал Компани Лимитед |
Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
|
|
IL274799B2
(en)
|
2017-11-22 |
2025-05-01 |
Gritstone Bio Inc |
Reducing junction epitope presentation for neoantigens
|
|
US11633473B2
(en)
|
2017-11-27 |
2023-04-25 |
Children's Medical Center Corporation |
Stimulator of Interferon Genes (STING) ligands and uses thereof
|
|
KR20200099178A
(ko)
*
|
2017-12-15 |
2020-08-21 |
얀센 바이오테크 인코포레이티드 |
Sting 작용제로서의 환상 다이뉴클레오티드
|
|
EP3727401A4
(en)
|
2017-12-20 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
|
AU2018392212B9
(en)
|
2017-12-20 |
2021-03-18 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
|
CN111727054A
(zh)
*
|
2018-01-04 |
2020-09-29 |
中央研究院 |
用于增加疗效的可与细胞结合的免疫佐剂
|
|
WO2019147509A1
(en)
*
|
2018-01-26 |
2019-08-01 |
The Regents Of The University Of California |
Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
|
|
KR20200118082A
(ko)
|
2018-02-02 |
2020-10-14 |
노파르티스 아게 |
암의 치료를 위한 sting 작용제 및 il-15/il15-ra의 병용물
|
|
US20210030870A1
(en)
*
|
2018-02-06 |
2021-02-04 |
Stipe Therapeutics Aps |
Modulation of p62 and sting activity
|
|
US12220462B1
(en)
|
2018-02-13 |
2025-02-11 |
Abionyx Pharma Sa |
Complexes for delivery of cyclic dinucleotides
|
|
US20190275134A1
(en)
|
2018-03-12 |
2019-09-12 |
Janssen Pharmaceuticals, Inc |
Vaccines against urinary tract infections
|
|
CN110272462B
(zh)
*
|
2018-03-15 |
2023-03-10 |
南开大学 |
制备化合物的方法
|
|
AU2019237508A1
(en)
|
2018-03-23 |
2020-10-01 |
Lonza Sales Ag |
Extracellular vesicles comprising STING-agonist
|
|
EP3774833A1
(en)
|
2018-03-27 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Modified cyclic dinucleotide compounds
|
|
EP3774834A1
(en)
|
2018-03-27 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
|
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
|
CN111971277B
(zh)
|
2018-04-03 |
2023-06-06 |
默沙东有限责任公司 |
作为sting激动剂的苯并噻吩及相关化合物
|
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
EP4353235A3
(en)
|
2018-04-25 |
2024-07-31 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
CN108310378A
(zh)
*
|
2018-04-28 |
2018-07-24 |
杭州星鳌生物科技有限公司 |
一类新型免疫联体抗肿瘤创新药物的制备及其应用
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2020012964A
(es)
|
2018-06-01 |
2021-02-16 |
Eisai R&D Man Co Ltd |
Metodos para el tratamiento de cancer de vejiga.
|
|
CN112672748A
(zh)
*
|
2018-06-20 |
2021-04-16 |
耶鲁大学 |
Rig-i激动剂以及使用其的治疗
|
|
MA53096A
(fr)
|
2018-07-03 |
2021-05-12 |
Ifm Due Inc |
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
|
|
MA53095A
(fr)
|
2018-07-03 |
2021-05-12 |
Ifm Due Inc |
Composés et compositions pour traiter des états pathologiques associés à une activité de sting
|
|
WO2020014127A1
(en)
|
2018-07-10 |
2020-01-16 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
EP3820992A2
(en)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
EP3837014B1
(en)
|
2018-08-16 |
2022-10-19 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
ES2974964T3
(es)
|
2018-08-16 |
2024-07-02 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
|
|
MX2020013322A
(es)
|
2018-08-16 |
2021-02-22 |
Eisai R&D Man Co Ltd |
Sales de compuestos y cristales de los mismos.
|
|
US11572360B2
(en)
|
2018-08-16 |
2023-02-07 |
Innate Tumor Immunity, Inc. |
Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
|
WO2020041720A1
(en)
|
2018-08-24 |
2020-02-27 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
|
EP4524154A3
(en)
|
2018-09-06 |
2025-06-04 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugates of cyclic dinucleotide derivatives
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
US20220031825A1
(en)
*
|
2018-09-17 |
2022-02-03 |
Quratis Inc. |
Immunological adjuvant and vaccine composition including sting agonist
|
|
WO2020061129A1
(en)
|
2018-09-19 |
2020-03-26 |
President And Fellows Of Harvard College |
Compositions and methods for labeling and modulation of cells in vitro and in vivo
|
|
CN110938104B
(zh)
|
2018-09-21 |
2024-07-12 |
上海迪诺医药科技有限公司 |
环状二核苷酸类似物、其药物组合物及应用
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
US20220412979A1
(en)
|
2018-10-29 |
2022-12-29 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
EP3873484B1
(en)
|
2018-10-29 |
2023-08-23 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
WO2020092633A1
(en)
|
2018-10-30 |
2020-05-07 |
Vanderbilt University |
Graft copolymers, methods of forming graft copolymers, and methods of use thereof
|
|
CN113348181A
(zh)
|
2018-10-31 |
2021-09-03 |
诺华股份有限公司 |
包含sting激动剂的dc-sign抗体缀合物
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
EP3891164A4
(en)
*
|
2018-12-07 |
2022-08-24 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2020117623A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
US20220033435A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
CN111423483B
(zh)
*
|
2019-01-10 |
2025-01-17 |
英诺生物制药(深圳)有限公司 |
环二核苷酸前药分子及其制备方法和应用
|
|
KR102815870B1
(ko)
|
2019-01-14 |
2025-05-30 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제
|
|
ES2981835T3
(es)
|
2019-01-14 |
2024-10-10 |
Innate Tumor Immunity Inc |
Quinazolinas sustituidas como moduladores de NLRP3, para su uso en el tratamiento del cáncer
|
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
KR20210114983A
(ko)
|
2019-01-14 |
2021-09-24 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
TW202043198A
(zh)
|
2019-01-17 |
2020-12-01 |
美商Ｉｆｍ Ｄｕｅ有限公司 |
用於治療與sting活性相關之病況的化合物及組合物
|
|
US10998091B2
(en)
|
2019-02-07 |
2021-05-04 |
Sandeep Patil |
Systems for monitoring compliance with a patch dosage regimen and methods of using the same
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
CN113574063B
(zh)
*
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸及其前药
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020191082A1
(en)
|
2019-03-18 |
2020-09-24 |
Janssen Pharmaceuticals, Inc. |
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
|
|
SG11202110303XA
(en)
|
2019-03-18 |
2021-10-28 |
Janssen Pharmaceuticals Inc |
Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
|
|
BR112021018694A2
(pt)
|
2019-03-21 |
2021-11-30 |
Codiak Biosciences Inc |
Vesículas extracelulares para distribuição de vacina
|
|
CA3133314A1
(en)
|
2019-03-21 |
2020-09-24 |
Codiak Biosciences, Inc. |
Extracellular vesicle conjugates and uses thereof
|
|
EP3941607A1
(en)
|
2019-03-21 |
2022-01-26 |
Codiak BioSciences, Inc. |
Process for preparing extracellular vesicles
|
|
EP3946324B1
(en)
|
2019-04-04 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
WO2020227421A1
(en)
*
|
2019-05-09 |
2020-11-12 |
Aligos Therapeutics, Inc. |
Modified cyclic dinucleoside compounds as sting modulators
|
|
WO2020229982A1
(en)
|
2019-05-10 |
2020-11-19 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
JP2022535743A
(ja)
|
2019-05-29 |
2022-08-10 |
アイエフエム デュー インコーポレイテッド |
Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
|
|
WO2021003445A1
(en)
|
2019-07-03 |
2021-01-07 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
EP3993834A1
(en)
|
2019-07-05 |
2022-05-11 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
AU2020324388A1
(en)
|
2019-08-02 |
2022-02-24 |
Mersana Therapeutics, Inc. |
Bis-[N-((5-carbamoyl)-1H-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as STING (Stimulator of Interferon Genes) agonists for the treatment of cancer
|
|
CA3149494A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
|
US20220305048A1
(en)
|
2019-08-26 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
EP3785719A1
(en)
*
|
2019-08-28 |
2021-03-03 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
New use of cyclic dinucleotides
|
|
EP4034247A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
WO2021062290A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
|
BR112022005614A2
(pt)
|
2019-09-25 |
2022-07-12 |
Codiak Biosciences Inc |
Composições de vesícula extracelular
|
|
JP2022551420A
(ja)
|
2019-09-25 |
2022-12-09 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用
|
|
US20220362368A1
(en)
|
2019-10-02 |
2022-11-17 |
Janssen Vaccines & Prevention B.V. |
Staphylococcus peptides and methods of use
|
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
CA3164751A1
(en)
|
2019-12-18 |
2021-06-24 |
Benjamin Joseph MORROW |
Compounds
|
|
US20230348458A1
(en)
|
2020-01-10 |
2023-11-02 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
HUE068985T2
(hu)
|
2020-01-16 |
2025-02-28 |
Janssen Pharmaceuticals Inc |
FIMH mutáns, ezt tartalmazó készítmények és ezek alkalmazása
|
|
KR20220162130A
(ko)
|
2020-02-28 |
2022-12-07 |
탈락 테라퓨틱스, 인크. |
트랜스글루타미나제-매개된 접합
|
|
WO2021177438A1
(ja)
|
2020-03-06 |
2021-09-10 |
第一三共株式会社 |
新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート
|
|
US20230114434A1
(en)
|
2020-03-13 |
2023-04-13 |
Codiak Biosciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
AU2021236763A1
(en)
|
2020-03-20 |
2022-10-06 |
Lonza Sales Ag |
Extracellular vesicles for therapy
|
|
BR112022019919A2
(pt)
|
2020-04-02 |
2023-02-14 |
Mersana Therapeutics Inc |
Conjugado de anticorpo-fármaco compreendendo agonistas de sting
|
|
KR20220167275A
(ko)
|
2020-04-10 |
2022-12-20 |
오노 야꾸힝 고교 가부시키가이샤 |
암 치료 방법
|
|
US11857618B2
(en)
|
2020-04-17 |
2024-01-02 |
Emory University |
Boosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway
|
|
IL298019A
(en)
|
2020-05-13 |
2023-01-01 |
Massachusetts Inst Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
WO2022032191A1
(en)
|
2020-08-07 |
2022-02-10 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
WO2022050300A1
(ja)
|
2020-09-02 |
2022-03-10 |
第一三共株式会社 |
新規エンド－β－Ｎ－アセチルグルコサミニダーゼ
|
|
US12036319B2
(en)
|
2020-09-08 |
2024-07-16 |
The Board Of Regents Of The University Of Texas System |
Polyvalent sting activating compositions and uses thereof
|
|
BR112023004819A2
(pt)
|
2020-09-17 |
2023-04-18 |
Janssen Pharmaceuticals Inc |
Composições de vacinas multivalentes e seus usos
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
US20230366794A1
(en)
|
2020-09-23 |
2023-11-16 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
EP4216993A2
(en)
|
2020-09-23 |
2023-08-02 |
Codiak BioSciences, Inc. |
Methods of producing extracellular vesicles
|
|
EP4228681A1
(en)
|
2020-10-14 |
2023-08-23 |
Boehringer Ingelheim International GmbH |
Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
|
|
EP3984535A1
(en)
|
2020-10-16 |
2022-04-20 |
Albert-Ludwigs-Universität Freiburg |
Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
|
|
JP2023546278A
(ja)
|
2020-10-20 |
2023-11-01 |
タイリガンド バイオサイエンス（シャンハイ）リミテッド |
多機能環状ジヌクレオチド及びその使用
|
|
CN115160392A
(zh)
*
|
2020-10-20 |
2022-10-11 |
泰励生物科技（上海）有限公司 |
多功能环二核苷酸及其用途
|
|
WO2022094262A1
(en)
|
2020-10-30 |
2022-05-05 |
Avacta Life Sciences Limited |
Fap-activated serum extended half-life therapeutic conjugates
|
|
AU2021374958A1
(en)
|
2020-11-09 |
2023-06-22 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
US20220211883A1
(en)
|
2020-12-17 |
2022-07-07 |
Trustees Of Tufts College |
Fap-activated radiotheranostics and uses related thereto
|
|
CN117529475A
(zh)
|
2021-01-08 |
2024-02-06 |
艾福姆德尤股份有限公司 |
用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
|
|
CA3207841A1
(en)
|
2021-01-12 |
2022-07-21 |
Janssen Pharmaceuticals, Inc |
Fimh mutants, compositions therewith and use thereof
|
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體－免疫賦活化劑共軛物之新穎製造方法
|
|
EP4313135A1
(en)
|
2021-04-01 |
2024-02-07 |
Janssen Pharmaceuticals, Inc. |
Production of e. coli o18 bioconjugates
|
|
US20240424090A1
(en)
|
2021-04-20 |
2024-12-26 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
EP4326769A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
US20220313724A1
(en)
*
|
2021-05-17 |
2022-10-06 |
Highlight Therapeutics, S.L. |
Compositions for intratumoral administration and related methods
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
|
CN114106140A
(zh)
*
|
2021-11-23 |
2022-03-01 |
哈尔滨医科大学附属肿瘤医院 |
一种表达特定sting异构体、细胞系、制备方法、用途
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
WO2023167238A1
(ja)
|
2022-03-02 |
2023-09-07 |
第一三共株式会社 |
Ｆｃ含有分子の製造方法
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
KR20250054799A
(ko)
|
2022-08-29 |
2025-04-23 |
다이이찌 산쿄 가부시키가이샤 |
변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
|
|
WO2024211577A1
(en)
|
2023-04-05 |
2024-10-10 |
Massachusetts Institute Of Technology |
Hybrid polymeric systems and methods of use thereof
|